Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome

Florence Wong, Thomas D. Boyer, Arun J. Sanyal, Stephen C. Pappas, Shannon Escalante, Khurram Jamil

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Background. Hepatorenal syndrome type 1 (HRS-1), a form of acute kidney injury (AKI) in cirrhosis, has a median survival of days to weeks if untreated. The impact of reduction in AKI stage on overall survival in cirrhosis, independent of HRS reversal, is unclear. Methods. The Randomized, placEbo-controlled, double-blind study to confirm the reVERSal of HRS-1 with terlipressin study assessed terlipressin versus placebo, both with albumin, as treatment for HRS-1 for ≤14 days. Renal dysfunction severity was categorized by AKI stage at enrollment. Baseline patient characteristics were evaluated as predictors of AKI improvement using a multivariate model; the association between AKI stage reduction and 90-day survival was assessed using linear regression. Results. A total of 184 patients (terlipressin: n ¼ 91; placebo: n ¼ 93) with similar numbers in AKI Stages 1-3 (terlipressin/ placebo, Stage 1: n ¼ 25/26; Stage 2: n ¼ 35/33; Stage 3: n ¼ 31/ 34) were included. Predictors of AKI improvement were absence of alcoholic hepatitis, baseline serum creatinine and male gender. Overall survival was not significantly different across AKI stages (range 53-65%). In patients with no AKI worsening, 90-day survival was consistently better when AKI improved independent of HRS reversal, regardless of the initial AKI stage, with patients with Stage 1 at initial diagnosis achieving the greatest clinical benefit. A significant association was observed between AKI reduction and overall 90-day survival (P ¼ 0.0022). Conclusions. A reduction in AKI stage, independent of HRS reversal, was sufficient to improve overall survival in patients with HRS-1. The goal for HRS-1 treatment should be less stringent than absolute HRS reversal.

Original languageEnglish (US)
Pages (from-to)1554-1561
Number of pages8
JournalNephrology Dialysis Transplantation
Issue number9
StatePublished - Sep 1 2020


  • Acute kidney injury
  • Hepatorenal syndrome type 1
  • Survival
  • Terlipressin

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this